Pre-Made Lenercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F for drug discovery and mechanism of action (MOA) research

Pre-Made Lenercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tumor necrosis factor alpha (TNF-¦Á) is a cytokine that has pleiotropic effects on various cell types. It has been identified as a major regulator of inflammatory responses and is known to be involved in the pathogenesis of some inflammatory and autoimmune diseases. Lenercept is a fusion protein combining the human p55 kDa TNF receptor and human IgG1 heavy chain, produced significant pain relief, reduction in swollen and tender joint counts, and improvement in physician- and patient-assessed disease activity scores.